dispatched RND transporter family member 2Genealiases: C15orf36 · DISPB · HsT16908 · LINC00594
Q-omics provides the consensus-scored DISP2 profile across patient tissues and cancer cell-line models. DISP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DISP2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, DISP2 RNA expression shows 17,514 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where DISP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DISP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DISP2 survival associations across molecular data types. DISP2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DISP2 RNA expression–survival associations across cancer types. High DISP2 expression shows unfavorable associations in ACC, UCEC, UCS, KIRC and BLCA, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DISP2 RNA expression.
This table summarizes DISP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DISP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DISP2 shows lower tumor expression in COAD and THCA and higher tumor expression in HNSC, LUAD, KIRC and KIRP. The COAD box plot shows higher DISP2 RNA expression in normal versus tumor tissue (log2 FC = −1.507, t-test p < 0.001).
This table shows molecular features associated with DISP2 in patient tissues and cancer cell lines. In patient samples, DISP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DISP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
